Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 49

Related Articles by Review for PubMed (Select 17541402)

1.

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.

Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A.

Leukemia. 2007 Aug;21(8):1658-68. Epub 2007 May 31.

PMID:
17541402
2.

JAK and MPL mutations in myeloid malignancies.

Tefferi A.

Leuk Lymphoma. 2008 Mar;49(3):388-97. doi: 10.1080/10428190801895360. Review.

PMID:
18297515
3.
4.

Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.

Levine RL, Wernig G.

Hematology Am Soc Hematol Educ Program. 2006:233-9, 510. Review.

5.
6.

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.

Kilpivaara O, Levine RL.

Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28. Review.

PMID:
18754026
7.

JAK2 and MPL mutations in myeloproliferative neoplasms.

Koppikar P, Levine RL.

Acta Haematol. 2008;119(4):218-25. doi: 10.1159/000140634. Epub 2008 Jun 20. Review.

PMID:
18566540
8.

JAK-2 mutations and their relevance to myeloproliferative disease.

Levine RL, Gilliland DG.

Curr Opin Hematol. 2007 Jan;14(1):43-7. Review.

PMID:
17133099
9.

JAK2 mutations and clinical practice in myeloproliferative neoplasms.

Tefferi A.

Cancer J. 2007 Nov-Dec;13(6):366-71. Review.

PMID:
18032973
10.

JAK-mutant myeloproliferative neoplasms.

Levine RL.

Curr Top Microbiol Immunol. 2012;355:119-33. doi: 10.1007/82_2011_170. Review.

PMID:
21823028
11.

Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.

Pikman Y, Levine RL.

Curr Opin Oncol. 2007 Nov;19(6):628-34. Review.

PMID:
17906464
12.

The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?

James C.

Hematology Am Soc Hematol Educ Program. 2008:69-75. doi: 10.1182/asheducation-2008.1.69. Review.

13.

Myeloproliferative disorders.

Levine RL, Gilliland DG.

Blood. 2008 Sep 15;112(6):2190-8. doi: 10.1182/blood-2008-03-077966. Review.

14.

Targeting myeloproliferative neoplasms with JAK inhibitors.

Pardanani A, Tefferi A.

Curr Opin Hematol. 2011 Mar;18(2):105-10. doi: 10.1097/MOH.0b013e3283439964. Review.

PMID:
21245760
15.

[Myeloproliferative diseases caused by JAK2 mutation].

Nagata K, Shimoda K.

Rinsho Byori. 2009 Apr;57(4):357-64. Review. Japanese.

PMID:
19489438
16.

A role for JAK2 mutations in myeloproliferative diseases.

Morgan KJ, Gilliland DG.

Annu Rev Med. 2008;59:213-22. Review.

PMID:
17919086
17.
18.

Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.

Tefferi A.

Am J Hematol. 2008 Jun;83(6):491-7. doi: 10.1002/ajh.21183. Review.

PMID:
18429051
19.

Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.

Tibes R, Bogenberger JM, Benson KL, Mesa RA.

Mol Diagn Ther. 2012 Oct;16(5):269-83. doi: 10.1007/s40291-012-0006-3. Review.

PMID:
23023734
20.

Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.

Spivak JL.

Ann Intern Med. 2010 Mar 2;152(5):300-6. doi: 10.7326/0003-4819-152-5-201003020-00008. Review.

PMID:
20194236
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk